<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1726">
  <stage>Registered</stage>
  <submitdate>24/10/2007</submitdate>
  <approvaldate>24/10/2007</approvaldate>
  <nctid>NCT00549497</nctid>
  <trial_identification>
    <studytitle>A Randomized Study Evaluating Steroid Hormone Levels, Safety And Tolerability Of GW870086X In Healthy Volunteers</studytitle>
    <scientifictitle>A Randomized, Double-blind, Placebo-controlled, Dose Ascending, 3-cohort Parallel Group Study to Measure the Systemic Cortisol Profile and Evaluate the Safety, Tolerability and Pharmacokinetics of GW870086X, Administered as Single Doses (12mg and 15mg), and Repeat Doses Over 3 Days (6mg, 12mg and 15mg) in Healthy Male Subjects</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>SIG110405</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Asthma</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - GW870086X

Other: GW870086X - 


Treatment: drugs: GW870086X


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Effect of GW870086X on cortisol levels (naturally produced steroid hormone) in the body during a single dose and after 3 days of dosing</outcome>
      <timepoint>3 days</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Safety &amp; tolerability measures: heart rate, blood pressure, ECG, safety laboratory tests, lung function</outcome>
      <timepoint>3 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Total urinary free cortisol excretion</outcome>
      <timepoint>over 24 hours on Day 1 and Day 3.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Serum osteocalcin weighted mean</outcome>
      <timepoint>over 24 hours on Day 3.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Fasting glucose</outcome>
      <timepoint>on Day 1</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>mRNA steroid responsive gene panel</outcome>
      <timepoint>3 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Plasma concentrations of GW870086X and GW870086X pharmacokinetic parameters (including AUC, Cmax, t1/2 and tmax).</outcome>
      <timepoint>3 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Plasma concentrations of GW870086X and derived pharmacokinetic parameters</outcome>
      <timepoint>3 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cortsiol urine concentrations</outcome>
      <timepoint>3 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Osteocalcin serum concentrations</outcome>
      <timepoint>3 days</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Inclusion criteria:

          -  Healthy male subjects

          -  Liver function tests normal

          -  18 - 45 years old

          -  Non smoker

          -  Can provide written informed consent

          -  Available to complete the whole trial

          -  Can use the inhalation device correctly

          -  Able to read, understand and write English</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>45</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Male</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>Exclusion criteria:

          -  Deemed suitable healthy subject

          -  History to sensitivity to the study medication

          -  Any history of breathing problems in adult life

          -  Participated in another trial within 30 days or 5 half-lives of the new chemical
             entity

          -  Exposed to more than 4 new chemical entities within 12 months

          -  Donated &gt;500 mL blood within 2 months of screening

          -  Haemoglobin level &lt; 13g/dl

          -  Use of prescription or non-prescription drugs within 7 days of first dose

          -  Taking drugs that significantly inhibit cytochrome P450 subfamily enzyme CYP3A4

          -  Drinks more than 4 units a day or 28 units a week

          -  Cannot use DISKHALER device correctly

          -  Positive HepB, HepC within 3 months of screening

          -  Positive HIV test

          -  Positive pre study drug/alcohol screen

          -  Significant cardiac conduction abnormalities

          -  Risk of non-compliance</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/09/2007</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>36</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/01/2008</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>QLD</recruitmentstate>
    <hospital>GSK Investigational Site - Herston</hospital>
    <postcode>4006 - Herston</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>GlaxoSmithKline</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>GW870086X is a novel inhaled steroid that has an improved safety profile over other steroids
      but is also less potent. This study will look at higher doses to confirm the improved safety
      profile.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00549497</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>GSK Clinical Trials</name>
      <address>GlaxoSmithKline</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>